Efficiency of perindopril arginine and indapamide retard in patients with nocturnal hypertension: The results of the study “Chronos”

Objective. To assess the antihypertensive efficiency of perindopril arginine and indapamide retard in patients with nocturnal hypertension (HTN). Design and methods. In the regional program “Chronos” of the open, multicenter, observational, non-controlled study, we included 196 patients with nocturnal hypertension (2nd degree — 59,4%; 3rd degree — 40,6%). Upon inclusion, instead of the previous therapy the patients received 10 mg perindopril arginine at night and 1,5 mg indapamide retard in the morning. The follow-up was 3 months, the efficiency and tolerability were assessed in 2 weeks, 1 and 3 months of therapy. Blood pressure (BP) was measured by Korotkoff method. Statistical analysis was performed with the use of the programs Microsoft Excel 2012, Statsoft Statistica 10.0. Results. At baseline, daytime median systolic BP was 165,5 (160; 180) mmHg, diastolic BP was 100 (90; 100) mmHg. After 2 weeks of treatment by perindopril arginine and indapamide retard, both daytime and nocturnal BP decreased (p < 0,05). The positive changes maintained for the whole follow-up period. Seven patients did not achieve target BP 1 month later. In these cases, additional therapy (other drug class medications) was prescribed. Conclusion. All patients demonstrated both daytime and nighttime BP decrease. In 73% patients there was no morning BP rise anymore. In 60% BP was normalized in patients who had been considered resistant. The combination therapy was well-tolerated.

1. Diagnosis and treatment of hypertension. Russian guidelines (fourth revision). Systemnye Gipertenzii = Systemic Hypertension. 2010;3:5–26. In Russian

2. Chazova IE, Zhernakova YV, Oschepkova EV, Shalnova SA, Yarovaya E, Konradi AO et al. The prevalence of cardiovascular disease in the Russian population of patients with arterial hypertension. Kardiologiia. 2014;10:4–12. doi:https://dx.doi. org/10.18565/cardio.2014.10.4–12 In Russian

3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age specific relevance of usual blood pressure to vascular mortality: meta-analyses of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9394):1129–1134.

4. Petrenko OV. Chronotherapy of hypertension: literature review. Journal of V. N. Karazin` KhNU. 2015;1154:71–78.

5. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. J Am Med Assoc. 1996;275(19):1507–1513

6. Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens. 1998;11 (11 Pt 1):1394–1404.

7. Sumova A, Sladek M, Polidarova L, Novakova M, Houdek P. Circadian system from conception till adulthood. Progress Brain Res. 2012;199:83–103. doi:10.1016/B978-0-444-59427-3.00005-8

8. Paulis L, Simko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res. 2007;56(6):671–684.

9. Takeda N, Maemura K. Circadian clock and cardiovascular disease. J Cardiol. 2011;57(3):249–256. doi:10.1016/j.jjcc. 2011.02.006

10. Pickering TG. The clinical significance of diurnal blood pressure variations: Dippers and nondippers. Circulation. 1990;81 (2):700–702.

11. Portaluppi F. The circadian organization of the cardio- vascular system in health and disease. Ind J Exp Biol. 2014;52(05): 395–398.

12. Kario K, Schwartz JE, Gerin W, Robayo N, Maceo E, Pickering TG. Psychological and physical stress-induced cardiovascular resctivity and diurnal blood pressure variation in women with different work shifts. Hypertens Res. 2002;25 (4):543–551.

13. Piper MA, Evans CV, Burda BU Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: an update systematic review for the U. S. Preventive Services Task Force. Ann Int Med. 2015;162 (3):192–204.

14. Head GA. Ambulatory blood pressure monitoring is ready to replace clinic blood pressure in the diagnosis of hypertension. Pro Side of the Argument. Hypertension. 2014;64(6):1175–1181. doi:10.1161/HYPERTENSIONAHA.114.03882

15. Fagard RH, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Night–day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens. 2009;23(10):645–653. doi:10.1038/jhh.2009.9

16. Roush GC, Fagard RH, Salles GF, Pierdomenico SD, Reboldi G, Verdecchia P et al. Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13 844 patients with hypertension. J Hypertens. 2014;32(12):2332– 2340. doi:10.1097/HJH.0000000000000355

17. Kario K., Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107(10):1401–1406.

18. Redon J. The importance of 24-hour ambulatory blood pressure monitoring in patients at risk of cardiovascular events. High Blood Press Cardiovasc Prevent. 2013;20(1):13–18. doi:10.1007/ s40292-013-0006-3

19. Xie JC, Yan H, Zhao Y-X, Liu XY. Prognostic value of morning BP surge in clinical events: a meta-analysis of longitudinal studies. J Stroke Cerebrovasc Dis. 2015;24(2):362–369. doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.09.001

20. Vernon G. The chronotherapy of hypertension: or the benefit of taking blood pressure tablets at bedtime. Br J Gen Pract 2017;67 (657):171. doi:https://doi.org/10.3399/bjgp17X690269

21. Roush GC. Fapohunda J, Kostis JB. Evening dosing of antihypertensive therapy to reduce cardiovascular events — a third type of evidence based on a systematic review and meta-analysis of randomized trials. J Clin Hypertens. 2014;16(8):561–568. doi:10. 1111/jch.12354

22. Smolensky MH, Hermida RC, Ayalab DE, Tiseo R, Portaluppi F. Administration–time-dependent effects of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit. 2010;15(4):173–180. doi:10.1097/ MBP.0b013e32833c7308

23. Lukyanov MM, Boitsov SA, Yakushin SS, Martsevich SY, Vorobiev AN, Zagrebelny AV et al. Concomitant cardiovascular diseases and antihypertensive treatment in outpatient practice (by the RECVASA Registry data). Rational Pharmacotherapy in Cardiology. 2016;12(1):4–15. In Russian

24. Fox KM; European trial ON reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788.

25. Rodriguez-Granillo GA, De Winter S, Bruining N, Ligthart JM, García-García HM, Valgimigli M et al. Effect of perindopril on coronary remodeling: insights from a multicentre, randomized study. Eur Heart J. 2007;28(19):2326–2331.

26. Morgan T, Anderson A, Jones E. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens. 1997;15(2):205–211.

27. Leonova MV, Belousov DYu, Steinberg LL, and the analytical group of the PIFAGOR study. Analysis of the clinical routine practice of antihypertensive therapy in Russia (according to the PIFAGOR III study). Pharmateka 2009;12:98– 103. In Russian

28. Martyniuk TV, Kolos IP, Chazova IE. on behalf of the co-investigators of the STRATEGY program. Efficacy and safety of a fixed combination of low-dose of perindopril/indapamide in patients with arterial hypertension in real clinical practice (multicentre, open, prospective study STRATEGY). Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2007;8:21–27. In Russian

29. Chazova IE, Ratova LG, Martynyuk ТV. The first results of the Russian study STRATEGY A (Russian program for assessing the efficacy of Noliprel A Forte in patients with high-risk arterial hypertension and insufficient control of blood pressure) is on the way to optimize antihypertensive therapy in high-risk hypertension patients. Systemnye Gipertenzii = Systemic hypertension. 2010;4:41–48. In Russian

30. Mourad JJ, Lameira D, Guillausseau PJ. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. Vasc Health Risk Manag. 2008;4 (2):4443–4451.

31. Dahlöf B, Gosse P, Gueret P, Dubourg O, de Simone G, Schmieder R et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23(11):2063–2070.

32. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G et al. Preterax in albuminuria regression (PREMIER) study Group. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003;41(5):1063–1071.

33. Patel A; ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829–840.